Ryan Walker

Structural basis for potency differences between GDF8 and GDF11.
Walker, R.G.; Czepnik, M.; Goebel, EJ; McCoy, JC; Vujic, A; Cho, M; Oh, J; Aykul, S; Walton, KL; Shang, G; Bernard, DJ; Hinck, AP; Harrison, CA; Martinez-Hackert, E; Wagers, AJ; Lee, RT; Thompson, T.B., Structural basis for potency differences between GDF8 and GDF11. BMC Biology 2017, 15(1), 19. (Pub Med)

Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation.    Walker, R.G.; Poggioli, T; Katsimpardi, L; Buchanan, SM; Oh, J; Wattrus, S; Heidecker, B; Fong, YW; Rubin, LL; Ganz, P; Thompson, T.B.; Wagers, AJ; Lee, RT., Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation. Circ Res. 2016, 118(7):1125-41. (Pub Med)

Role of Conserved Prolines in Apolipoprotein A-IV Structure and Function.
Deng, X.; Walker, R.G.; Morris, J.; Davidson, W.S.; Thompson, T.B., Role of conserved proline residues in human apolipoprotein A-IV structure and function. J Biol Chem 2015, [Epub ahead of print]. (Pub Med)

Alternate Binding Modes for GASP-mediated Inhibition of Myostatin.
Walker, R.G.; Angerman, E.B.; Kattamuri, C.; Lee, Y.S.; Lee, S.J.; Thompson, T.B., Alternative binding modes identified for growth and differentiation factor-associated serum protein (GASP) family antagonism of myostatin. J Biol Chem 2015, 290(12), 7506-16.

Structure of Apolipoprotein A-IV Determined by Cross-linking, Molecular Dynamics, and SAXS
Walker, R.G.; Deng, X.; Melchior, J.T.; Morris, J.; Tso, P.; Jones, M.K.; Segrest, J.P.; Thompson, T.B.; Davidson, W.S., The structure of human apolipoprotein A-IV as revealed by stable isotope-assisted cross-linking, molecular dynamics, and small angle x-ray scattering. J Biol Chem 2014, 289(9), 5596-608. (Pub Med)

Patent Evaluation of Myostatin Binding Proteins.
Walker, R.G.; Thompson, T.B., Fibronectin-based scaffold domain proteins that bind myostatin: a patent evaluation of WO2014043344. Expert Opin Ther Pat 2015, 25(5), 619-24. (Pub Med)

Myostatin Stimulates C2C12 Myoblast Proliferation.
Rodgers, B.D.; Wiedeback, B.D.; Hoversten, K.E.; Jackson, M.F.; Walker, R.G.; Thompson, T.B., Myostatin stimulates, not inhibits, C2C12 myoblast proliferation. Endocrinology 2014, 155(3), 670-5. (Pub Med)

Analysis of Heparin-Follistatin Binding and Interactions.
Zhang, F.; Beaudet, J.M.; Luedeke, D.M.; Walker, R.G.; Thompson, T.B.; Linhardt, R.J., Analysis of the interaction between heparin and follistatin and heparin and follistatin-ligand complexes using surface plasmon resonance. Biochemistry 2012, 51(34), 6797-803. (Pub Med)

 


Kristof Nolan

Structure of NBL1.
Nolan, K.; Kattamuri, C.; Luedeke, D.M.; Angerman, E.B.; Rankin, S.A.; Stevens, M.L.; Zorn, A.M.; Thompson, T.B., Structure of neuroblastoman suppressor of tumorigenicity 1 (NBL1): insights for the functional variability across bone morphogenetic protein (BMP) antagonists. J Biol Chem 2015, 290(8), 4759-71. (Pub Med)

DAN-family Review.
Nolan, K.; Thompson, T.B., The DAN family: modulators of TGFß signaling and beyond. Protein Sci 2014, 23(8), 999-1012. (Pub Med)

Structure of Protein Related to Dan and Cerberus (PRDC).
Nolan, K.; Kattamuri, C.; Luedeke, D.M.; Jagpal, A.; Zhang, F.; Linhardt, R.; Kenny, A.P.; Zorn, A.M.; Thompson, T.B., Structure of protein related to dan and cerberus: insights into the mechanism of bone morphogenetic protein antagonism. Structure 2013, 21(8), 1417-29. (Pub Med) PDB: 4JPH

DAN Family Antagonists Exist as Noncovalent Dimers.
Kattamuri, C.; Luedeke, D.M.; Nolan, K.; Rankin, S.A.; Greis, A.; Zorn, A.M.; Thompson, T.B., Members of the dan family are BMP antagonists that form highly stable noncovalent dimers. J Mol Bio 2012, 424(5), 313-27. (Pub Med)

Myostatin in Complex with FSTL3.
Cash, J.N.; Angerman, E.B.; Kattamuri, C.; Nolan, K.; Zhao, H.; Sidis, Y.; Keutmann, H.T.; Thompson, T. B., Structure of myostatin:follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding. J Biol Chem 2012, 287(2), 1043-53. (Pub Med) PDB: 3SEK


Xiaodi 'Andy' Deng

Role of Conserved Prolines in Apolipoprotein A-IV Structure and Function.
Deng, X.; Walker, R.G.; Morris, J.; Davidson, W.S.; Thompson, T.B., Role of conserved proline residues in human apolipoprotein A-IV structure and function. J Biol Chem 2015, [Epub ahead of print]. (Pub Med)

Structure of Apolipoprotein A-IV Determined by Cross-linking, Molecular Dynamics, and SAXS
Walker, R.G.; Deng, X.; Melchior, J.T.; Morris, J.; Tso, P.; Jones, M.K.; Segrest, J.P.; Thompson, T.B.; Davidson, W.S., The structure of human apolipoprotein A-IV as revealed by stable isotope-assisted cross-linking, molecular dynamics, and small angle x-ray scattering. J Biol Chem 2014, 289(9), 5596-608. (Pub Med)

SAXS of Apolipoprotein A-IV Reveals Importance of Termini.
Deng X.; Morris J.; Chaton, C.; Schroder, G.F.; Davidson, W.S.; Thompson T.B., Small-angle X-ray scattering of apolipoprotein A-IV reveals the importance of its termini for structural stability.J Biol Chem 2013, 288(7), 4854-66. (Pub Med)

Structure of Apolipoprotein A-IV.
Deng, X.; Morris, J.; Dressmen, J.; Tubb, M.R.; Tso, P.; Jerome, W.G.; Davidson, W.S.; Thompson, T. B., The structure of dimeric apolipoprotein A-IV and its mechanism of self-association. Structure 2012, 20(5), 767-79. (Pub Med) PDB: 3S84

Dehydration and Diffraction of Apolipoprotein A-IV Crystals.
Deng X.; Davidson W.S.; Thompson, T.B., Improving the diffraction of apoA-IV crystals through extreme dehydration.Acta Crystallogr Sect F Struct Biol Cryst Commun 2012, 68(Pt 1), 105-10. (Pub Med)


Jennifer Cash

Small Molecule Screening for Inhibitors of Myostatin and Activin A.
Cash, J.N.; Angerman, E.B.; Keutmann, H.T.; Thompson, T.B., Development of a small-molecule screening method for inhibitors of cellular response to myostatin and activin A. J Biomol Screen 2013, 18(7), 837-44. (Pub Med)

Contribution of Follistatin's Domains towards Antagonism.
Cash, J.N.; Angerman, E.B.; Keutmann, H.T.; Thompson, T.B., Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism. Mol Endocrinol 2012, 26(7), 1167-78. (Pub Med)

Myostatin in Complex with FSTL3.
Cash, J.N.; Angerman, E.B.; Kattamuri, C.; Nolan, K.; Zhao, H.; Sidis, Y.; Keutmann, H.T.; Thompson, T. B., Structure of myostatin:follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding. J Biol Chem 2012, 287(2), 1043-53. (Pub Med) PDB: 3SEK

Myostatin in Complex with FST288.
Cash, J.N.; Rejon, C.A.; McPherron, A.C.; Bernard, D.J.; Thompson, T. B., The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding. Embo J 2009, 28(17), 2662-76. (Pub Med) PDB: 3HH2